At the end stage, also known as the "spent phase ... In about 3% of people with polycythemia vera, the disease changes into acute myeloid leukemia. Leukemia happens because the bone marrow ...

But even scarier is the prospect of feeling fine, and then — all of a sudden and seemingly out of the blue — learning that ...

Billy Bean and Catalina Villegas, MLB executives who are trying to end intolerance and prejudices in baseball, are now fighting for their lives.

In the field of myelodysplastic syndromes (MDS), there are a number of investigational studies designed with the hope of ...

REFRaME-P1 is a registration-enabling study evaluating the efficacy and safety of luvelta in infants and children under 12 years of age with CBF/GLIS AML. This will be a global study, with the ...

acute myeloid leukemia (AML). ROCKVILLE, Md., May 06, 2024--GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies ...

Legend Biotech is a global, clinical-stage biopharmaceutical company ... T cell lymphoma, acute myeloid leukemia and infectious diseases. Multiple first-in-human studies are underway or planned ...

Topline results from registration-directed trial of ziftomenib in R/R NPM1-mutant AML expected in early 2025; Phase 1 results published in The ...

Nov. 5, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage ... leukemia, as well as the expected readout of topline pivotal data from patients with R/R mNPM1 AML.

Last month, the Paris-based pharmaceutical giant licensed rights to Alphamedix, a clinical-stage radiopharmaceutical ... such as multiple myeloma, acute myeloid leukemia, and certain types of ...

For the three months ended September 30, 2024, Syndax reported a net loss attributable to common stockholders of $84.1 million, or $0.98 per share, compared to a net loss attributable to common ...